Clarion Pharmaceuticals Inc.

Clarion Pharmaeuticals Inc.

Thaddeus P Pruss

Andrew C Peterson

Parvin T Yazdi

James A Will

A method of replenishing plasmalogens in mammals comprising treatment with a plasmalogen-replenishing-effective amount of one or more stantially pure monoethers of glycerols and their carboxylic acid ester derivatives of Formula I:

Nutritional supplements for replenishing plasmalogens

.alpha.-Tocopherylphosphocholine and salts thereof have been discovered to possess antiviral, anti-fungal, anti-inflammatory, PAF-antagonist, and ultra-violet radiation-blocking activities. The compound and salts have also been discovered to be capable of forming liposomes. The present invention thus provides methods of treating viral and fungal infections, inflammatory disorders and pathophysiological conditions due to PAF activity in a mammal by administering to the mammal .alpha.-tocopherylphosphocholine or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions comprising .alpha.-tocopherylphosphocholine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Further, the invention provides liposomes which comprise .alpha.-tocopherylphosphocholine or a salt thereof as a structural component of the liposome bilayer.

Pharmaceutical compositions, novel uses, and novel form of

Disclosed is a method of treating respiratory diseases comprising treating the lungs with an therapeutically-effective amount of .alpha.-tocopheryl-phosphocholine or a pharmaceutically-acceptable salt thereof, wherein the amount is administered is effective to make breathing easier.

Treatment of respiratory diseases utilizing

Retinoyl substituted glycerophosphoethanolamines are disclosed having the general Formula I: ##STR1## wherein one of A, B or C is a fatty ether substituent, one is a natural or synthetic retinoid ester substituent, and one is a phosphoethanolamine substituent, provided that A, B and C are each a different substituent. The optical and geometric isomers of compounds of Formula I and the pharmaceutically acceptable salts of the compounds, including the isomers, are also disclosed. The compounds (including the isomers thereof) and salts of the invention exhibit anti-tumor, anti-psoriatic and anti-inflammatory activities.

Retinoid glycerol phospholipid conjugates

.alpha.-tocopherolphosphocholine and salts thereof have been discovered to possess anti-viral, anti-fungal, anti-inflammatory and PAF-antagonist activities. The compound and salts have also been discovered to be capable of forming liposomes. The present invention thus provides methods of treating viral and fungal infections, inflammatory disorders and pathophysiological conditions due to PAF activity in a mammal by administering to the mammal .alpha.-tocopherolphosphocholine or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions comprising .alpha.-tocopherolphosphocholine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Further, the invention provides liposomes which comprise .alpha.-tocopherolphosphocholine or a salt thereof as a structural component of the liposome bilayer.

The present invention relates to the treatment and prophylaxis of viral infections with fatty alkyl and alkenyl ether glycerophosphoethanolamines bearing a 3-(2-imidazolinyl)-2-imidazolinyl or 2-imidazolinyl substituent on the ethanolamine nitrogen.

Method for treating viral infection

A method of inhibiting degeneration of neural cells comprising treating the cells with an effective degeneration-inhibiting amount of one or more compounds of Formula I: ##STR1## wherein R is a C.sub.12 to C.sub.22 linear or branched alkyl group, or pharmaceutically-acceptable salts thereof is disclosed.

Treatment for the inhibition of neuro-degenerative disease states

The use of phospholipids of the following formula to reduce the viscosity of mucus in a patient is described: ##STR1## wherein one of X, Y, or Z represent: ##STR2## in which each R represents hydrogen or methyl, and each of the other two of X, Y, or Z represents --CO--R.sup.1 in which R.sup.1 represents linear or branched C.sub.11-21 alkyl or C.sub.11-21 alkenyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo, C.sub.1-6 linear or branched alkoxy or cyano.

Method of lowering the viscosity of mucus

A fibrogen-free substrate having as a hemostatic agent on a surface thereof a mixture of a clot-promoting amount of thrombin and an amount of epsilon aminocaproic acid (EACA) effective to accelerate the rate of blood clotting induced by the thrombin is useful as a hemostatic patch which is safe, inexpensive and which rapidly controls bleeding from a wound. A patch which rapidly stanches the flow of blood from a lesion on a parenchymal organ by pressing it against the surface of the organ for 3-5 minutes, is produced by applying thrombin, EACA and CaCl.sub.2 to a rigid sheet of biodegradable foam, such as an absorbable gelatin sponge, and compressing the dry sheet to produce a flexible sheet which conforms to the contour of the organ without the necessity of pre-moistening. The EACA raises the pH of the acidic fluid associated with the wound and thereby accelerates the activation of the thrombin.

Hemostatic patch

A fibrogen-free substrate having as a hemostatic agent on a surface thereof a mixture of a clot-promoting amount of thrombin and an amount of epsilon aminocaproic acid (EACA) effective to accelerate the rate of blood clotting induced by the thrombin is useful as a hemostatic patch which is safe, inexpensive and which rapidly controls bleeding from a wound. A patch which rapidly stanches the flow of blood from a lesion on a parenchymal organ by pressing it against the surface of the organ for 3-5 minutes, is produced by applying thrombin, EACA and CaCl.sub.2 to a rigid sheet of biodegradable foam, such as an absorbable gelatin sponge, and compressing the dry sheet to produce a flexible sheet which conforms to the contour of the organ without the necessity of pre-moistening. The problem associated with thrombin-fibrinogen glues of adhesion of the wounded surface of the organ to adjacent tissue is avoided by applying the hemostatic agent to only the wound-contacting face of the sheet.

Growing community of inventors

Madison, WI, United States of America

Thaddeus P Pruss